Holen Sie sich die Stockscreener-App
2.555
1.38%
0.025
Schlusskurs vom Vortag:
$2.53
Offen:
$2.56
24-Stunden-Volumen:
124.17K
Relative Volume:
0.14
Marktkapitalisierung:
$110.36M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-1.1457
EPS:
-2.23
Netto-Cashflow:
$-129.10M
1W Leistung:
-0.19%
1M Leistung:
+18.75%
6M Leistung:
+62.34%
1J Leistung:
+100.39%
1-Tages-Spanne:
$2.55
$2.57
1-Wochen-Bereich:
$2.52
$2.59
52-Wochen-Spanne:
$0.89
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
Firmenname
Repare Therapeutics Inc
Sektor
Branche
Telefon
(857) 412-7018
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Vergleichen Sie RPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
2.56 | 109.06M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.41 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.73 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-09 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-12 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-17 | Fortgesetzt | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Stifel | Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2020-10-28 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-14 | Eingeleitet | Cowen | Outperform |
| 2020-07-14 | Eingeleitet | Goldman | Neutral |
| 2020-07-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - ulpravda.ru
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - ulpravda.ru
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - ulpravda.ru
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - MarketScreener
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Order Flow Trends Show Accumulation in Graphite India LimitedPortfolio Risk Assessment & Free Powerful Profit Generation - earlytimes.in
Will Repare Therapeutics Inc. stock gain from lower inflationEarnings Surprise Analysis & Our Picks = Your Future Gains - bollywoodhelpline.com
Repare Therapeutics Announces Resignation of Chief Scientific Officer - TradingView — Track All Markets
Repare Therapeutics Inc. Announces Resignation Ofmichael Zinda as Chief Scientific Officer, Effective December 31, 2025 - marketscreener.com
Why Repare Therapeutics Inc. stock is considered a top pickWeekly Market Report & Stepwise Swing Trade Plans - DonanımHaber
XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR - MSN
Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Geopolitical Influence & Safe Swing Trade Setups - Улправда
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights - Sahm
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-RPTX, FRGE, CSGS, FIZN - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Benzinga
Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Sahm
Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval - TipRanks
Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):